Clinical trials: SARS-COV-2 Infection
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19
This is a randomized, double-blinded, phase Ⅳ clinical trial of COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Life Sciences Co. , Ltd.
- Trial name
- NCT05165966
- Testing
- High-dosage of COVID-19 vaccine (Vero cell), Inactivated, Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
SARS-CoV-2 Infection
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19.
- Trial name
- NCT05799495
- Testing
- PF-07817883
- Where
- 53 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Covid19, SARS (Severe Acute Respiratory Syndrome)
Proxalutamide Treatment for Hospitalized COVID-19 Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04728802
- Testing
- Proxalutamide
- Where
- 8 sites in Brazil
- Volunteers
- 645 people
- Sponsor
- Applied Biology, Inc.
Covid19, Respiratory Disease
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019…
- Conditions
- Covid19, Respiratory Disease, Immune System, Immunomodulator
- Trial name
- NCT04701502
- Testing
- Viusid, Asbrip, Standard Care
- Where
- 2 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Healthy Participant
Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants
The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.
- Trial name
- NCT04962022
- Testing
- PF-07321332/ritonavir, Itraconazole
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
COVID-19
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05249777
- Testing
- TD0069 hard capsule
- Where
- 2 sites in Vietnam
- Volunteers
- 573 people
- Sponsor
- Sao Thai Duong Joint Stock Company
COVID-19 Vaccine, COVID-19
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.
- Trial name
- NCT05873374
- Testing
- 50 μg Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
The purpose of this study is to evaluate the safety, immunogenicity, and efficacy of Nanocovax vaccine in volunteer subjects 18 years of age and older.
- Trial name
- NCT04922788
- Testing
- Nanocovax
- Where
- Vietnam
- Volunteers
- 13,006 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
SARS (Severe Acute Respiratory Syndrome), COVID-19
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO).
- Trial name
- CORSER (NCT04325646)
- Testing
- Human Biological samples
- Where
- 21 sites in France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Coronavirus Disease (COVID-19)
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
The primary objective of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28.
- Trial name
- NCT04569786
- Testing
- V590
- Where
- 7 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild-to-moderate COVID-19
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of…
- Trial name
- NCT04414124
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- Kaleido Biosciences
Severe/Very Severe COVID-19 Illness
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness.
- Trial name
- NCT04337359
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.